A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Thus, the foundation of the food chain typically consists of primary producers. Primary producers, or autotrophs, utilize energy derived from either sunlight or inorganic chemical compounds to create complex organic compounds, such as starch, for energy. Because the sun's light is necessary for photosynthesis, most life could not exist if the sun disappeared. Even so, it has recently been discovered that there are some forms of life, chemotrophs, that appear to gain all their metabolic energy from chemosynthesis driven by hydrothermal vents, thus showing that some life may not require solar energy to thrive. Chemosynthetic bacteria and archaea use hydrogen sulfide and methane from hydrothermal vents and cold seeps as an energy source (just as plants use sunlight) to produce carbohydrates; they form the base of the food chain in regions with little to no sunlight. Regardless of where the energy is obtained, a species that produces its own energy lies at the base of the food chain model, and is a critically important part of an ecosystem. Higher trophic levels cannot produce their own energy and so must consume producers or other life that itself consumes producers. In the higher trophic levels lies consumers (secondary consumers, tertiary consumers, etc.). Consumers are organisms that eat other organisms. All organisms in a food chain, except the first organism, are consumers. Secondary consumers eat and obtain energy from primary consumers, tertiary consumers eat and obtain energy from secondary consumers, etc.
Former Essendon vice-captain Mark McVeigh was similarly forthright in his praise, claiming Robinson's knowledge of the club's fitness program was "squeaky clean". "I can honestly tell you that everything I took I knew 100 per cent that it was within the WADA and AFL doping regulations," McVeigh continued, affirming his belief that Robinson had done nothing wrong. Following his sacking Robinson began a legal campaign against the club, on the grounds of unfair dismissal. On Thursday 2 October, Essendon reached a $1 million settlement with Robinson to end his unfair dismissal claim. A trial had previously been set for 10 November and several high profile figures, such as Andrew Demetriou and Gillon McLachlan, were expected to testify. In court documents Robinson claimed that an Essendon public relations strategy had been formulated to portray himself and Stephen Dank as "rogue operators" during their tenure.
=== Antifungal effect === Its antifungal effect is thought to derive from its ability to disrupt membrane transport by blocking the proton pump that energizes the transport mechanism. A study from 2011 showed that antifungal effects of zinc pyrithione work by copper toxicity mechanism that targets critical iron–sulphur proteins.
November 10: Todor Zhivkov, the Communist leader of Bulgaria, is removed from office after 35 years in power. November 17–28: The Velvet Revolution brought the end of the authoritarian one-party rule in Czechoslovakia. December 2: End of the Second Malayan Emergency with the Peace Agreement of Hat Yai 1989. December 3: At the end of the Malta Summit, Soviet leader Mikhail Gorbachev and US President George H. W. Bush declare that a long-lasting era of peace has begun. Many observers regard this summit as the official beginning of the end of the Cold War. December 10: The Mongolian Revolution begins when Mongolians held peaceful demonstrations to end the one-party rule in the country. December 14: Democracy is restored in Chile. December 16–25: Rioters during the Romanian Revolution overthrow the Communist government of Nicolae Ceauşescu, executing him and his wife, Elena. Romania was the only Eastern Bloc country to violently overthrow its Communist government or to execute its leaders. December 20: The United States initiates Operation Just Cause. December 24: The First Liberian Civil War begins. December 25: The Romanian Communist Party, the former ruling party of Romania, is dissolved. December 29: Václav Havel becomes President of the now free Czechoslovakia.
== Function == YAP1 is a transcriptional co-activator and its proliferative and oncogenic activity is driven by its association with the TEAD family of transcription factors, which up-regulate genes that promote cell growth and inhibit apoptosis. Several other functional partners of YAP1 were identified, including RUNX, SMADs, p73, ErbB4, TP53BP2, LATS1/2, PTPN14, AMOTs, and ZO1/2. YAP1 and its close paralog, TAZ (WWTR1), are the main effectors of the Hippo tumor suppressor pathway. When the pathway is activated, YAP1 and TAZ are phosphorylated on a serine residue and sequestered in the cytoplasm by 14-3-3 proteins. When the Hippo pathway is not activated, YAP1/TAZ enter the nucleus and regulate gene expression. It is reported that several genes are regulated by YAP1, including Birc2, Birc5, connective tissue growth factor (CTGF), amphiregulin (AREG), Cyr61, Hoxa1 and Hoxc13. YAP/TAZ have also been shown to act as stiffness sensors, regulating mechanotransduction independently of the Hippo signalling cascade. As YAP and TAZ are transcriptional co-activators, they do not have DNA-binding domains. Instead, when inside the nucleus, they regulate gene expression through TEAD1-4 which are sequence-specific transcription factors that mediate the main transcriptional output of the Hippo pathway. The YAP/TAZ and TEAD interaction competitively inhibits and actively dissociates the TEAD/VGLL4 interaction which functions as a transcriptional repressor.
Sources: en.wikipedia.org
==== Inverted-V ==== When operating on the midvault of the nose, it is important to reattach the upper lateral cartilages to the nasal septum. Failure to do so may cause the upper lateral cartilages to collapse inward and caudaully, creating an upside-down "V" shadow. Inverted-V deformities are typically corrected with spreader grafts to restore the internal nasal valve.
=== Active site === Histidinol is held inside the active site thanks to a zinc ion, but the zinc ion does not participate in the catalysis otherwise. The zinc ion is held in place by His262, Gln259, Asp360 and His419 (which, in homodimeric histidinol dehydrogenases, comes from the other monomer). Histidinol itself is held in place by His327 and His367 from one moment unit and Glu414 from the other monomer unit. A Cys residue has been implicated in the catalytic mechanism of the second oxidative step. However, according to newer studies with histidinol dehydrogenase from E. coli, the mechanism is catalyzed by four bases, B1-B4. His327 acts as the first base, deprotonating histidinol's hydroxyl group. Concomitantly, hydride is abstracted from histidinol by NAD+, which is then exchanged for a second NAD+ molecule. Glu325 acts as the second base, deprotonating a molecule of water, which then attacks histidinol. At the same time, His327 (now protonated) donates a proton to the aldehydic oxygen, which results in a gem-diol. After then, His327 again deprotonates one of the hydroxyl groups and NAD+ abstracts a proton from the reactive carbon atom. This series of steps oxidizes the hydroxyl group to a carboxylic acid.
Glycoproteins have differential levels of glycosylations and adsorb SDS more unevenly at the glycosylations, resulting in broader and blurred bands. Membrane proteins, because of their transmembrane domain, are often composed of the more hydrophobic amino acids, have lower solubility in aqueous solutions, tend to bind lipids, and tend to precipitate in aqueous solutions due to hydrophobic effects when sufficient amounts of detergent are not present. This precipitation manifests itself for membrane proteins in a SDS-PAGE in "tailing" above the band of the transmembrane protein. In this case, more SDS can be used (by using more or more concentrated sample buffer) and the amount of protein in the sample application can be reduced. An overloading of the gel with a soluble protein creates a semicircular band of this protein (e. g. in the marker lane of the image at 66 kDa), allowing other proteins with similar molecular weights to be covered. A low contrast (as in the marker lane of the image) between bands within a lane indicates either the presence of many proteins (low purity) or, if using purified proteins and a low contrast occurs only below one band, it indicates a proteolytic degradation of the protein, which first causes degradation bands, and after further degradation produces a homogeneous color ("smear") below a band. The documentation of the banding pattern is usually done by photographing or scanning. For a subsequent recovery of the molecules in individual bands, a gel extraction can be performed.
== Herbal == Eryngium planum is used in European folk medicine as a diuretic, a stimulant, and an appetizer owing to its essential oils, and bioactive compounds, and in this usage it may be known as Eryngii plani herba or Eryngii plani radix.
Sources: en.wikipedia.org
== Goals of Pharmacometabolomics == Pharmacometabolomics is thought to provide information that complements that gained from other omics, namely genomics, transcriptomics, and proteomics. Looking at the characteristics of an individual down through these different levels of detail, there is an increasingly more accurate prediction of a person's ability to respond to a pharmaceutical compound. The genome, made up of 25 000 genes, can indicate possible errors in drug metabolism; the transcriptome, made up of 85,000 transcripts, can provide information about which genes important in metabolism are being actively transcribed; and the proteome, >10,000,000 members, depicts which proteins are active in the body to carry out these functions. Pharmacometabolomics complements the omics with direct measurement of the products of all of these reactions, but with perhaps a relatively smaller number of members: that was initially projected to be approximately 2200 metabolites, but could be a larger number when gut derived metabolites and xenobiotics are added to the list. Overall, the goal of pharmacometabolomics is to more closely predict or assess the response of an individual to a pharmaceutical compound, permitting continued treatment with the right drug or dosage depending on the variations in their metabolism and ability to respond to treatment. Pharmacometabolomic analyses, through the use of a metabolomics approach, can provide a comprehensive and detailed metabolic profile or "metabolic fingerprint" for an individual patient.
BRD-6929, also widely known as "compound 60" (Cpd-60 or Cmpd60), is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It has been described in the past as the prototypical selective HDAC1 and HDAC2 inhibitor. However, subsequent findings suggest that BRD-6929 may not actually be selective for HDAC1 and HDAC2 over HDAC3.
=== August === 6 August – Tom O'Connor, journalist, author, senior citizens' advocate and local politician, president of Grey Power (2016–2018), Waimate District Councillor (since 2013) (born 1944). 8 August Judy Bailey, pianist, composer, jazz musician and educator (Sydney Conservatorium of Music), and television presenter (Play School) (born 1935). Peter Lester, sailor, sailing coach and commentator, OK dinghy world champion (1977), Admiral's Cup winner (1987, 1993) (born 1954). 10 August – Patrick Waddington, Russian linguist, literary critic and historian (Victoria University of Wellington) (born 1934). 13 August – Grant Tavinor, philosopher (Lincoln University) (born c. 1973). 15 August – John Rowan, lawyer, King's Counsel (since 1997) (born 1944). 16 August – Janet Grieve, biological oceanographer (New Zealand Oceanographic Institute, NIWA), New Zealand Association of Scientists president (1998–2000), World Association of Copepodologists president (2008–2011) (born 1940). 17 August – John Bartley, cinematographer (Lost, The X Files, The Chronicles of Riddick), Emmy Award (1996) (born 1947). 18 August Lloyd Ashby, rugby union player (Southland, national team) (born 1931). Lindsay Sparks, cricketer (Central Districts, Auckland) and rugby union player (Marlborough) (born 1944). 19 August – Tony Smith, legal scholar (University of Reading, University of Cambridge, Victoria University of Wellington) (born 1947). 21 August Evelyn Attwood, tennis player (born 1924). Keith Nelson, rugby union player (Otago, Auckland, national team) and dentist (born 1938).
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.